ArticleAnnals of general psychiatry2025
Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study.
Article in Annals of general psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-population validation of European GWAS loci for metabolic syndrome in Chinese schizophrenia.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveAntipsychotic-induced metabolic disturbance (AIMD) represents a prevalent adverse effect associated with antipsychotic medications, with genetic factors partially contributing to the variability in susceptibility observed among patients with schizophrenia (SCZ). This study examined the effect of ANKK1 (rs1800497) polymorphism on glucose and lipid metabolism in Chinese patients diagnosed with SCZ and undergoing olanzapine treatment.
methodsA cohort of 104 SCZ patients receiving olanzapine treatment was recruited retrospectively for the investigation. The polymorphism in the ANKK1 (rs1800497) gene were identified and analyzed. The clinical and demographic characteristics of subjects with ANKK1 (rs1800497) genotypes were compared at baseline. The associations between ANKK1 rs1800497 genotypes and glucose and lipid indicators at baseline were examined. Following a 4-week olanzapine treatment, changes in glucose and lipid indicators among subjects with ANKK1 (rs1800497) genotypes were evaluated. Additionally, the relationship between these genotypes and the alterations in glucose and lipid indicators after olanzapine treatment was analyzed.
resultsAt baseline, individuals carrying the T allele of the ANKK1 rs1800497 polymorphism exhibited significantly lower serum total cholesterol (TC) levels compared to those possessing the CC genotype (P = 0.024). Moreover, under an additive allelic model (coded as 1 = CC, 2 = CT, 3 = TT), the TT genotype of the ANKK1 rs1800497 polymorphism demonstrated a negative correlation with serum TC (r = -0.237, P = 0.015) and glucose levels (r = -0.276, P = 0.005). Furthermore, following olanzapine treatment, patients who were carriers of the TT genotype of ANKK1 rs1800497 had a smaller reduction in glucose levels compared to those with the CC genotype (P = 0.027). Additionally, the TT genotype of the ANKK1 rs1800497 polymorphism demonstrated a positive correlation with changes in glucose levels (r = 0.237, P = 0.015).
conclusionThese findings suggest a potential association between the ANKK1 rs1800497 polymorphism and blood glucose variability in Chinese patients with SCZ undergoing olanzapine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.